KDR and Miyoshi myopathy: Sorafenib, a multi-targeted receptor tyrosine kinase inhibitor, targeting VEGFR-2, VEGFR-3, RAF, PDGFR-B, Flt-3, and cKit exerts a significant anti-MM activity and synergize with other anti-MM drugs [71].